Hematology

Latest News

After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

June 26th 2025

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Multi-hit TP53 mutations are a significant negative prognostic factor for patients with both MPN and AML, the new study found. | Image credit: MdBabul - stock.adobe.com
Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

June 20th 2025

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose
January 19th 2019

Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose

Laura Joszt, MA
Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.
Site Logo
January 19th 2019

Policy

Updates from the annual ASH meeting, December 2018.
Tisagenlecleucel Shows Promise for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
January 17th 2019

Tisagenlecleucel Shows Promise for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David Bai, PharmD
Published results confirm the efficacy of tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.
Maintenance Therapy for Multiple Myeloma Needs Improvement Beyond Lenalidomide, Study Says
January 12th 2019

Maintenance Therapy for Multiple Myeloma Needs Improvement Beyond Lenalidomide, Study Says

David Bai, PharmD
Maintenance therapy with lenalidomide remains a standard of care for patients with multiple myeloma. However, optimizing maintenance therapy in this setting is required as a result of lenalidomide’s lack of overall survival benefit and improvement in outcomes for patients with high-risk cytogenic abnormalities, according to a recent study.
BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference
January 8th 2019

BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference

Jaime Rosenberg
Bristol-Meyers Squibb (BMS) and Celgene kicked off the 37th Annual JP Morgan Healthcare Conference by discussing their leading drugs, near-term launches, and early pipeline assets.
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages
January 5th 2019

Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages

As a physician, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, was able to leverage his medical and scientific knowledge during treatment for his chronic lymphocytic leukemia (CLL), and he encourages other patients to educate themselves on their illnesses in order to receive the best care.
Radiotherapy Plus Chemotherapy Improves Survival in Pediatric Patients With Hodgkin Lymphoma
January 5th 2019

Radiotherapy Plus Chemotherapy Improves Survival in Pediatric Patients With Hodgkin Lymphoma

Laura Joszt, MA
Pediatric patients with early-stage Hodgkin lymphoma who are treated with chemotherapy followed by radiotherapy, known as combined modality therapy, have an improved 5-year survival rate compared with patients treated with chemotherapy alone.
Dr Elizabeth Griffiths Outlines Recent Approvals in AML
January 4th 2019

Dr Elizabeth Griffiths Outlines Recent Approvals in AML

Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center discusses recent approvals for acute myeloid leukemia (AML).
Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Later Tumors
December 29th 2018

Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Later Tumors

David Bai, PharmD
Children with Hodgkin lymphoma who are treated during childhood and survive to adulthood have higher incidence rates of breast, lung, colorectal, and thyroid cancer than the general population, according to a recent study.
Dr Alison Moskowitz Discusses Survival Disparities in Hodgkin Lymphoma
December 29th 2018

Dr Alison Moskowitz Discusses Survival Disparities in Hodgkin Lymphoma

Patients who are over 60 with Hodgkin lymphoma have much lower survival rates than patients who are under 60, explained Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center.
Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS
December 28th 2018

Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS

Laura Joszt, MA
Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.
Dr Brian Koffman Highlights Incredible Responses to CLL Treatments
December 20th 2018

Dr Brian Koffman Highlights Incredible Responses to CLL Treatments

There have been incredible responses to treatments for chronic lymphocytic leukemia (CLL), but there remains a tremendous unmet need for patients, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
Diabetes, Cancer Interviews Among Most-Watched Videos of 2018
December 20th 2018

Diabetes, Cancer Interviews Among Most-Watched Videos of 2018

Laura Joszt, MA
Throughout the year, The American Journal of Managed Care® (AJMC®) offered a number of video programs, including Peer Exchange discussions and interviews, on a range of topics. Here are the most-watched videos published by AJMC® in 2018.
NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward
December 19th 2018

NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward

Jaime Rosenberg
During the 60th American Society of Hematology Annual Meeting & Exposition held December 1-4 in San Diego, California, Norman Sharpless, MD, director, National Cancer Institute (NCI), brought attention to several advances made in hematologic malignancies over the past year and highlighted 4 areas of focus going forward.
Ibrutinib Regimens Have Superior PFS Compared With Chemoimmunotherapy in Older Patients With Untreated CLL
December 13th 2018

Ibrutinib Regimens Have Superior PFS Compared With Chemoimmunotherapy in Older Patients With Untreated CLL

David Bai, PharmD
Ibrutinib-containing regimens have similar overall survival rates but significantly higher progression-free survival (PFS) rates at 2 years compared with bendamustine plus rituximab.
Myelofibrosis Survival After Discontinuing Ruxolitinib Differs Based on Reason for Discontinuation
December 12th 2018

Myelofibrosis Survival After Discontinuing Ruxolitinib Differs Based on Reason for Discontinuation

Jaime Rosenberg
Following failure with ruxolitinib, there are limited treatment options available and among these patients who fail on the treatment, prognosis is unfavorable, particularly among those who started ruxolitinib with advanced stage disease, according to a study presented at the 60th American Society of Hematology Annual Meeting & Exposition.
ELOQUENT-3: Adding Elotuzumab to Pomalidomide, Dexamethasone Improves PFS in R/R Multiple Myeloma
December 8th 2018

ELOQUENT-3: Adding Elotuzumab to Pomalidomide, Dexamethasone Improves PFS in R/R Multiple Myeloma

David Bai, PharmD
ELOQUENT-3 trial results found that adding elotuzumab to pomalidomide and dexamethasone improved progression-free survival (PFS) and overall response rate in patients with multiple myeloma that had relapsed from or were refractory to (R/R) lenalidomide and a proteasome inhibitor.
Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis
December 7th 2018

Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis

Jaime Rosenberg
According to a study presented at the 60th American Society of Hematology Annual Meeting & Exposition, held December 1-4 in San Diego, California, a World Health Organization–defined diagnosis of primary myelofibrosis may help better identify patients who may need strict monitoring during treatment with ruxolitinib.
FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation
December 3rd 2018

FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation

Laura Joszt, MA
Once-daily gilteritinib pills have been approved to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Approximately 25% to 30% of patients with AML have this mutation, which is associated with an aggressive form of the disease and carries a higher risk of relapse.
Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse
December 1st 2018

Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse

David Bai, PharmD
In patients who relapse after allogeneic hematopoietic stem-cell transplantation, the therapeutic benefits that transplantation provide is diminished through mechanisms that remain unclear. A new study analyzed the genetic and epigenetic alterations of leukemic cells to determine any common features of relapse after transplantation
FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML
November 27th 2018

FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML

Laura Joszt, MA
FDA has recently approved 2 new treatments for patients age 75 and older who are newly diagnosed with AML and have other chronic health conditions or diseases that may mean they cannot use intensive chemotherapy.
Site Logo
November 27th 2018

Research to Look Out for at ASH 2018

Jaime Rosenberg
From December 1-4, hematology professionals from across the globe will convene in San Diego, California for the American Society of Hematology annual meeting to present and discuss their research and latest developments in malignant and non-malignant hematology. Here’s what to look out for during the meeting.
AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B
November 23rd 2018

AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B

David Bai, PharmD
AMT-061, an AAV5 vector containing factor IX (FIX)-Padua variant, has been shown to increase FIX activity to threshold FIX levels sufficient to significantly reduce the risk of bleeding events without the risk of adverse immune reactions.
Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease
November 20th 2018

Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease

Laura Joszt, MA
A new investigational drug has demonstrated high response rates in patients with a rare but highly aggressive blood disease that currently has no approved therapies, according to new research led by investigators at The University of Texas MD Anderson Cancer Center.
Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy
November 17th 2018

Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy

Since chimeric antigen receptor (CAR) T-cell therapy is still in early development there are benefits and risks that eligible patients will have to weigh, including the durable response against the limited amount of data and toxic side effects, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma
November 17th 2018

FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma

Allison Inserro
The FDA announced Friday it expanded the approved use of brentuximab vedotin (Adcetris) in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma, using a new review process designed to increase efficiency.
CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma
November 15th 2018

CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma

David Bai, PharmD
When used in combination with rituximab, Hu5F9-G4 (5F9), a humanized monoclonal anti-CD47 antibody, promotes durable objective and complete response rates in lymphoma while also having minimal adverse events (AE), according to a phase 1b study published in New England Journal of Medicine.
Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers
November 13th 2018

Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers

Laura Joszt, MA
Patients with blood cancers are burdened with higher costs than patients with other cancers, and spending in blood cancers does not return to precancer levels, according to a new study from the Leukemia & Lymphoma Society.
Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma
November 7th 2018

Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA
Daratumumab, a human CD38-directed monoclonal antibody, has been confirmed as safe in a population of heavily pretreated patients with multiple myeloma who received access to the treatment before the medication was commercially available, according to an early access treatment protocol study published in Cancer.
ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens
November 7th 2018

ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens

David Bai, PharmD
Children and adolescents with acute lymphoblastic leukemia (ALL) face an increased risk of obesity and growth impairment from the disease and during ALL treatment, regardless of exposure to cranial irradiation, according to a recent study.
<1
...
131415161718192021
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo